Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Balasch, J. González-Merlo.
Análogos de la GnRH: agonistas y antagonistas.
Prog Obstet Ginecol, 42 (1999), pp. 607-610
[2.]
R. Felberbaum, K. Diedrich.
Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists.
Hum Reprod, 14 (1999), pp. 201-221
[3.]
C. Albano, P. Platteau, P. Devroey.
Gonadotropin-releasing hormone antagonist: how good is the new hope?.
Curr Opin Obstet Gynecol, 13 (2001), pp. 257-262
[4.]
Z. Blumenfeld.
Gonadotropin-releasing hormone antagonists instead of agonists: a change for the better?.
Fertil Steril, 76 (2001), pp. 443-444
[5.]
Group The European Recombinant LH Study.
Recombinant human luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.
J Clin Endocrinol Metab, 89 (2001), pp. 2607-2618
[6.]
F. Olivennes, J. Belaisch-Allart, J.C. Emperaire, H. Dechaud, S. Álvarez, L. Moreau, et al.
Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
Fertil Steril, 73 (2000), pp. 314-320
[7.]
C. Albano, R.E. Felberbaum, J. Smitz, H. Rithmüller-Winzen, J. Engel, K. Diedrich, et al.
Ovarian stimulation with HMG: results of a prospective phase III European study comparing the luteinizing hormone-releasing hormone (LH-RH)-antagonist cetrorelix and the LHRH-agonist buserelin.
Hum Reprod, 15 (2000), pp. 526-531
[8.]
B. Mannaerts, E. van Hooren, P. Boerrigter.
Ganirelix in assisted reproduction: new treatment regimens and options.
Ovulation induction 2000, pp. 167-177
[9.]
A. Templeton, J.K. Morris.
Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization.
N Engl J Med, 339 (1998), pp. 573-577
[10.]
L.A. Schieve, H.B. Peterson, S.F. Meikle, G. Jeng, I. Danel, N.M. Burnett, et al.
Live-birth rates and multiplebirth risk using in vitro fertilization.
Jama, 282 (1999), pp. 1832-1838
[11.]
S. Kol.
Embryo implantation and GnRH antagonists: GnRH antagonists in ART: lower embryo implantation?.
Hum Reprod, 15 (2000), pp. 1881-1882
[12.]
E.R. Hernández.
Embryo implantation and GnRH antagonists. Embryo implantation: the Rubicon for GnRH antagonists.
Hum Reprod, 15 (2000), pp. 1211-1216
[13.]
D. De Jong, N.S. Macklon, M.J.C. Eijkemans, B.M.J.L. Mannaerts, H.J.T. Coelingh-Bennink, B.C.J.M. Fause, et al.
Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and varios doses of the gonadotropin-releasing hormone antagonists ganirelix (Orgalutran/Antagon).
Fertil Steril, 75 (2001), pp. 688-693
[14.]
Ganirelix® Dose-Finding Study Group.
A double-blind, randomized, dose finding study to assess the efficacy of the GnRH antagonist Ganirelix® (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon®).
Hum Reprod, 13 (1998), pp. 3023-3031
[15.]
F. Raga, E.M. Casañ, J. Kruessel, Y. Wen, F. Bonilla-Musoles, M.L. Polan.
The role of gonadotropin-releasing hormone in murine preimplantation embryonic development.
Endocrinology, 140 (1999), pp. 3705-3712
Copyright © 2001. Sociedad Española de Ginecología y Obstetricia